A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc. (NYSE:MRK ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

The Handmaid's Tale's final season saw a revolution come to Gilead, with the abused women of this dystopia rising up to ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...